Thomas Wagner

Thomas Wagner

Auto-generated profile, based on publicly available information

Thomas Wagner

Department of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JLJakob Lauritsen
Jakob Lauritsen
MHMerete Kjaer Hansen
Merete Kjaer Hansen
MBMikkel Bandak
Mikkel Bandak
MKMichael Bay Kreiberg
Michael Bay Kreiberg
JSJulie Wang Skøtt
Julie Wang Skøtt
GDGedske Daugaard
Gedske Daugaard
PURPOSE: To analyze the risk of cardiovascular disease (CVD) after treatment of male germ cell cancer (GCC). METHODS: Clinical data were extracted from the Danish Testicular Cancer database. For each patient, 10 men matched on date of birth were identified in the Danish normal population by risk-set sampling. Cardiovascular risk factors, CVD, and associated deaths were identified in Danish registries. The association between treatment and outcomes was analyzed by separate Cox models for each outcome. Cancer treatment was included as a time-varying covariate. RESULTS: We included 5,185 patients with GCC and 51,850 men in the normal population. Median follow-up was 15.8 years. Treatment with bleomycin-etoposide-cisplatin (BEP; n = 1,819) was associated with increased risks of hypertension and hypercholesterolemia. Hazard ratios (HRs) of CVD < 1 year after initiation of BEP treatment were as follows: myocardial infarction (HR, 6.3; 95% CI, 2.9 to 13.9), cerebrovascular accident (HR, 6.0; 95% CI, 2.6 to 14.1), and venous thromboembolism (HR, 24.7; 95% CI, 14.0 to 43.6). One year after BEP treatment, the risk of CVD decreased to normal levels, but after 10 years, increasing risks were found for myocardial infarction (HR, 1.4; 95% CI, 1.0 to 2.0) and cardiovascular death (HR, 1.6; 95% CI, 1.0 to 2.5). Radiotherapy (n = 780) increased the risk of diabetes at long-term follow-up (HR, 1.4; 95% CI, 1.0 to 2.0) but not that of other outcomes. With surveillance (n = 3,332), cardiovascular risk factors, CVD, and cardiovascular death data were comparable to that of the normal population. CONCLUSION: Treatment with BEP was associated with highly increased risks of CVD < 1 year after treatment start and mildly increased risks after 10 years of follow-up. Radiotherapy increased the risk of diabetes but not incident CVD. The risk of CVD in patients followed in a surveillance program was comparable to that of the normal population.

8 March 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MCMichal Chovanec
Michal Chovanec
JLJakob Lauritsen
Jakob Lauritsen
MBMikkel Bandak
Mikkel Bandak
COChristoph Oing
Christoph Oing
GKGry Gundgaard Kier
Gry Gundgaard Kier
GDGedske Daugaard
Gedske Daugaard

4 December 2019 in BJU International
Verified
Journal Article
Open access
PDF file
JBJoost M. Blok
Joost M. Blok
IPIlse Pluim
Ilse Pluim
GDGedske Daugaard
Gedske Daugaard
TWThomas Wagner
Thomas Wagner
KJKatarzyna Jóźwiak
Katarzyna Jóźwiak
SHSimon Horenblas
Simon Horenblas
Objective: To systematically review the literature on the prognostic value of lymphovascular invasion (LVI) and embryonal carcinoma (EC) for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour (CS I NSGCT). Materials and methods: The PubMed, Embase (OVID) and SCOPUS databases were searched up to March 2019. Studies reporting on the association between LVI and/or EC and occult metastatic disease were considered for inclusion. The quality and risk of bias were evaluated by the Quality in Prognosis Studies tool. Results: We screened 5287 abstracts and 207 full‐text articles. We included 35 studies in the narrative synthesis and 24 studies in a meta‐analysis. LVI showed the strongest effect. Pooled rates of occult metastasis were 47.5% and 16.9% for LVI‐positive and LVI‐negative patients, respectively (odds ratio [OR] 4.33, 95% confidence interval [CI] 3.55–5.30; P < 0.001). Pooled rates of occult metastasis were 33.2% for EC presence and 16.2% for EC absence (OR 2.49, 95% CI 1.64–3.77; P < 0.001). Pooled rates of occult metastasis were 40.0% for EC >50% and 20.0% for EC <50% (OR 2.62, 95% CI 1.93–3.56; P < 0.001). Conclusions: LVI is the strongest risk factor for relapse. The prognostic value of EC is high, but there is no common agreement on how to define this risk factor. Both EC presence and EC >50% have similar ORs for occult metastasis. This shows that the assessment of EC presence is sufficient for the classification of EC.

1 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TWThomas Wagner
Thomas Wagner
BTBirgitte Grønkær Toft
Birgitte Grønkær Toft
JLJakob Lauritsen
Jakob Lauritsen
MBMikkel Bandak
Mikkel Bandak
ICIb Jarle Christensen
Ib Jarle Christensen
GDGedske Daugaard
Gedske Daugaard
PURPOSE: Approximately 20% of patients with clinical stage I seminoma relapse. Tumor size and rete testis invasion have been identified as risk factors for relapse. However, the level of evidence supporting the use of these risk factors in clinical decision making is low. Previous studies have been hampered by selection bias and variable pathology reporting that limit interpretation and generalization of results. We assessed prognostic factors for relapse in an unselected nationwide population-based setting with centralized pathology review. METHODS: Patients with clinical stage I seminoma diagnosed from January 2013 to December 2018 were identified in the prospective Danish Testicular Cancer database. By linkage to the Danish National Pathology Registry, histologic slides from the orchiectomy specimens were retrieved and reviewed blinded to the clinical outcome. Clinical data were obtained from medical records with follow-up until July 2022. The association between prespecified potential clinical and histopathologic prognostic factors and relapse was assessed by the use of Cox regression analysis. RESULTS: Of 924 patients included, 148 (16%) patients relapsed during a median follow-up of 6.3 years. Invasion of the testicular hilum (rete testis and hilar soft tissue), lymphovascular invasion, and elevated preorchiectomy levels of β-human chorionic gonadotropin and lactate dehydrogenase were independent predictors of relapse. The estimated 5-year risk of relapse ranged from 6% in patients with no risk factors to 62% in patients with all four risk factors with tumor extension into the hilar soft tissue of the testicular hilum. After internal model validation, the prognostic model had an overall concordance statistic of 0.70. CONCLUSION: The provided prognostic factors could replace current risk factors in guidelines and be used in future studies investigating risk-adapted follow-up and treatment strategies.

6 November 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
TWThomas Wagner
Thomas Wagner
GSGlenda Scandura
Glenda Scandura
ARAmy Roe
Amy Roe
LBLuis Beltran
Luis Beltran
JSJonathan Shamash
Jonathan Shamash
DBDaniel Berney
Daniel Berney

17 March 2024 in European Journal of Cancer
Verified
Journal Article
Open access
TWThomas Wagner
Thomas Wagner
BTBirgitte Grønkær Toft
Birgitte Grønkær Toft
JLJakob Lauritsen
Jakob Lauritsen
MBMikkel Bandak
Mikkel Bandak
ICIb Jarle Christensen
Ib Jarle Christensen
GDGedske Daugaard
Gedske Daugaard
Approximately 30% of patients with clinical stage I non-seminoma (CSI-NS) relapse. Current risk stratification is based on lymphovascular invasion (LVI) alone. The extent to which additional tumor characteristics can improve risk prediction remains unclear. To determine the most important prognostic factors for relapse in CSI-NS patients. Population-based cohort study including all patients with CSI-NS diagnosed in Denmark between 2013 and 2018 with follow-up until 2022. Patients were identified in the prospective Danish Testicular Cancer database. By linkage to the Danish National Pathology Registry, histological slides from the orchiectomy specimens were retrieved. Histological slides were reviewed blinded to the clinical outcome. Clinical data were obtained from medical records. The association between prespecified potential prognostic factors and relapse was assessed using Cox regression analysis. Model performance was evaluated by discrimination (Harrell's C-index) and calibration. Of 453 patients included, 139 patients (30.6%) relapsed during a median follow-up of 6.3 years. Tumor invasion into the hilar soft tissue of the testicular hilum, tumor size, LVI and embryonal carcinoma were independent predictors of relapse. The estimated 5-year risk of relapse ranged from < 5% to > 85%, depending on the number of risk factors. After internal model validation, the model had an overall concordance statistic of 0.75. Model calibration was excellent. The identified prognostic factors provide a much more accurate risk stratification than current clinical practice, potentially aiding clinical decision-making.